The UN adoption of the SDGs in 2015 signaled a strong commitment of member countries to the expanded access to essential health service agenda and definitively recognized the critical role of medicines in achieving UHC. The SDGs call for countries to “achieve universal health coverage, including financial risk protection, access to quality essential health care services and access to safe, effective, quality and affordable essential medicines and vaccines for all”. This paper seeks to highlight the key functional areas of pharmaceutical management, the critical components of the pharmaceutical system, and the management considerations needed to facilitate the attainment of UHC targets.
Pharmaceutical management considerations for expanded coverage of essential health services and financial protection programs
by Aubrey Clark, MPH; Mohan P. Joshi, MBBS, MSc, MD Strong health systems are necessary to help prevent and mitigate epidemics, including the oft-overlooked epidemic of antimicrobial resistance. This post originally appeared on MSH’s Global Health Impact Blog as part of a new series on improving the health of the poorest and most vulnerable women, girls, families, […]
In Ukraine in recent years, failed rounds of centralized public tenders for pharmaceuticals and blockage of public funds in antimonopoly litigations were regarded as a harbinger of the impending crisis in the public health sector. The Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program was requested to step in and provide technical assistance to improve the system of public pharmaceutical procurement and enhance the expertise of the selected regional health administrations and individual health care facilities. Framework contracting was viewed as the most effective procurement technique to ensure value for money in the contexts of decentralization and diverse regional specifics. SIAPS led the implementation of framework contracting into the oblast procurement practices in two oblasts, with the ultimate goal of bringing systemic changes into the national health procurement system.
These guidelines provide instructions for applicants preparing a Common Technical Document (CTD) for the registration of medicines for submission to the Directorate General of Drug Administration (DGDA). The document describes how to organize applications based on the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines on the CTD. The CTD is currently applicable only to human, not veterinary, medicines.
Incorporating RxSolution into Pre-service Instruction on Medicines Supply Management in South Africa
By Bright Phiri, SIAPS Communications Officer; Katelyn Payne, SIAPS Project Associate; and Susan Putter, SIAPS Principal Technical Advisor A serious deficit of pharmacy support personnel in South Africa has highlighted the need to create new career opportunities in the field of pharmaceutical services provision. According to the South African Pharmacy Council, there are approximately 14,213 […]
Strengthening the TB pharmaceutical management system and ensuring patients’ uninterrupted access to anti-TB medicines in Uzbekistan
By Shirin Kakayeva, SIAPS Technical Associate and Dr. Archil Salakaia, SIAPS Central Asia Portfolio Manager Uzbekistan is one of 18 high-priority countries in the WHO’s European region, and is among 27 high-burden multidrug-resistant tuberculosis (MDR-TB) countries in the world. As the uninterrupted supply of anti-TB medicines is necessary for the survival of TB patients, pharmaceutical management […]
According to the 2013 World Malaria Report, malaria incidence and mortality rates were reduced by about 31% and 49%, respectively, in the World Health Organization (WHO) African Region between 2000 and 2012. These substantial reductions occurred as a result of a major scale-up of vector control interventions, diagnostic testing, and treatment with artemisinin-based combination therapies (ACTs). However, much remains to be done. The disease still took an estimated 627,000 lives in 2012, mostly children under five years of age in Africa.
Working closely with the President’s Malaria Initiative (PMI) both in Washington and in PMI focus countries, the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program aims to ensure the availability of quality pharmaceutical products and effective pharmaceutical services in support of PMI objectives. To this end, and based on PMI’s malaria program priorities, SIAPS endeavors to improve pharmaceutical governance, build capacity to manage malaria products, strengthen information management, strengthen financing strategies and mechanisms to improve access to malaria medicines, and improve the quality of pharmaceutical services provided to malaria patients.
The SIAPS technical approach emphasizes health systems strengthening with a special focus on improving metrics, monitoring and evaluation (M&E), developing the capacity of local governments and organizations, and increasing country ownership. Through this approach, SIAPS aims to promote the availability and use of malaria products, including ACTs, rapid diagnostic tests (RDTs), and medicines for severe malaria.
This report briefly describes the major activities that SIAPS conducted at the global level and in each of the above mentioned countries and regions between July and September 2014.
The West and Central African regions have a low HIV prevalence. Because of the low number of patients on ART and limited technical and financial support, these regions have experienced frequent stock-outs of ARVs posing a serious risk to patients on ART and increasing the risk of HIV drug resistance in the region. As a key step in addressing this challenge, the West Africa Regional Health Office of the US Agency for International Development is providing support through the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program to address the recurring pharmaceutical supply management issues by supporting the regional coordination mechanism and the development and implementation of an early warning system (EWS) for antiretrovirals (ARVs) and HIV and AIDS related commodities.
As part of project startup, SIAPS conducted a situational analysis in Burkina Faso, Cameroon, Guinea, Niger, and Togo to gain an understanding of the current capacity for HIV and AIDS commodities management and supply. Also analyzed was the readiness of the HIV and AIDS commodities information management systems to provide the information necessary for routine monitoring of HIV and AIDS product availability in the region.
By Luciana Maxim, SIAPS Technical Consultant; Marie Paule Fargier, SIAPS Country Project Director; and Serigne Diagne, SIAPS Project Director Prior to 2013, Guinea’s public health facilities faced prolonged stock-outs of antimalarial medicines and health commodities. This was due in part to a shortage of products in the country, but also resulted from substandard reporting of […]
Ensuring the Availability of Life-Saving Commodities in a Fragile State In December 2013, the fragile peace that held the newly independent country of South Sudan collapsed into renewed fighting. Since then, violence has led to massive outflows of people to nearby Ethiopia and the economy has steadily deteriorated in the absence of oil revenues. Throughout […]
The 3rd Biennial Scientific Conference on Medical Products Regulation in Africa (SCOMRA), which took place November 27–28, 2017, in Accra, […]
The director of the Department of Pharmacy, Medicines, and Diagnostics (DPMED) wishes to adopt suitable software to strengthen the registration system […]
In the last five years, SIAPS has provided technical assistance to the Namibia Medicines Regulatory Council (NMRC) to strengthen its capacity […]